Shona Banda cured her terminal Crohn’s disease with cannabis

Image result for shona banda

“Shona Banda was diagnosed with Crohn’s disease… She underwent several surgeries and was put on several pharmaceuticals, but her condition worsened progressively until she was considered terminal. She was bedridden… wasting away… She was waiting to die.

She managed to see Rick Simpson’s Run from the Cure…” 

“RUN FROM THE CURE: The Rick Simpson Story – A Film by Christian Laurette”  https://www.youtube.com/watch?v=aGjC4HReFL0

“Although she had been smoking marijuana to ease pain and help her sleep and eat, she had no way of making the oil, which required a pound of marijuana to produce the two ounces of cannabis oil she would need to heal.

Shona was in a funk about the lack of enough hemp to make her own oil when her husband noticed specks of oil residue in the inside of the vaporizer’s glass globe cover.

So she took the inhalation tube out of the vaporizer and sealed it, then simply collected those little blobs of oil from the inside of the glass globe with a spatula.

She did this three times a day, putting the collected oil residue into a capsule and taking it. After a very few days, Shona could walk without a cane. Soon she began eating and sleeping better and putting on weight. It wasn’t long before she was completely weened off all her pharmaceuticals.

She started a journal as she began getting better. The journal has become a book called Live Free or Die. The title is a reference to health freedom. Now she is very healthy and active.”

http://www.naturalnews.com/043718_chrons_disease_cannabis_shona_banda.html

“Crohn’s Disease Survivor Shona Banda Tells How Medical Marijuana Oil Helps Her “Live Free””  https://www.youtube.com/watch?v=x_otUB7pVMA

“Ben Swann Radio: Shona Banda Explains Her Remarkable Story On How Cannabis Oil Saved Her Life. After being diagnosed with Crohn’s disease in 2002, Shona Banda went through the struggles that many suffer with when battling the autoimmune disease. On the Ben Swann Radio Show, Ben and Shona discussed her tribulations while suffering from the disease and her immediate experiences after finding the cure to her disease.”
http://benswann.com/ben-swann-radio-shona-banda-explains-her-remarkable-story-on-how-cannabis-oil-saved-her-life/#ixzz32d6WqrPM

https://www.facebook.com/shona.banda

https://www.facebook.com/pages/Shona-Bandas-Live-Free-or-Die/146496222049591

http://www.thctotalhealthcare.com/category/crohns-disease/

 

Cannabis Proves Effective In Treating Crohn’s Disease According To New Study

cannibis crohn's disease drug

“A new clinical study published in the journal Pharmacology and by the National Institute of Health has found that cannabis is effective in treating Crohn’s disease, which is a form of inflammatory bowel disease (IBD)…

The study, entitled: “Cannabis Finds Its Way into Treatment of Crohn’s Disease”  is co-authored by Rudolf Schicho, PhD and M. Storr, both of the Institute of Experimental and Clinical Pharmacology, Medical University of Graz in Graz, Austria.

In the study abstract, Schicho and Storr note that In ancient medicine, cannabis was widely used to treat and cure bowel disturbances and inflammation, and a recent clinical study now shows that the medicinal herb Cannabis sativa lived up to expectations and proved to be highly efficient in cases of inflammatory bowel diseases.”

http://bionews-tx.com/news/2014/01/29/cannabis-proves-effective-treating-crohns-disease-according-new-study/

 http://www.thctotalhealthcare.com/category/crohns-disease/

Cannabinoid-induced autophagy regulates suppressor of cytokine signaling (SOCS)-3 in intestinal epithelium.

“Autophagy is a catabolic process involved in homeostatic and regulated cellular protein recycling and degradation via the lysosomal degradation pathway. Emerging data associates impaired autophagy, increased activity in the endocannabinoid system and upregulation of suppressor of cytokine signaling (SOCS)-3 protein expression during intestinal inflammatory states. We have investigated whether these three processes are linked. By assessing the impact of phyto-cannabinoid cannabidiol (CBD), synthetic cannabinoid (ACEA) and endocannabinoid (AEA) on autophagosome formation, we explored whether these actions were responsible for cyclic SOCS3 protein levels. Our findings show that all three cannabinoids induce autophagy in a dose-dependent manner in fully differentiated CaCo2 cells, a model of mature intestinal epithelium. ACEA and AEA induced canonical autophagy, which was cannabinoid receptor (CB)-1 mediated. In contrast, CBD was able to bypass both the CB1 receptor and the canonical pathway to induce autophagy, albeit to a lesser extent. Functionally, all three cannabinoids reduced SOCS3 protein expression, which was reversed by blocking both early and late autophagy. In conclusion, the regulatory protein, SOCS3, is itself regulated by autophagy and cannabinoids play a role in this process, which could be important when considering therapeutic applications for the cannabinoids in inflammatory conditions.”

http://www.ncbi.nlm.nih.gov/pubmed/24833710

Cannabichromene and tetrahydrocannabinol determination in mouse blood and brain by gas chromatography-mass spectrometry.

“Cannabichromene (CBC) is a phytocannabinoid, the second most abundant cannabinoid quantitatively in marijuana. CBC has been shown to produce antinociception and anti-inflammatory effects…”

 http://www.ncbi.nlm.nih.gov/pubmed/21871159

Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors.

“Delta-9 tetrahydrocannabinol (Delta(9)-THC) and (-)-cannabidiol ((-)-CBD) are major constituents of the Cannabis sativa plant with different pharmacological profiles…

We tested a series of (+)- and (-)-CBD derivatives for central and peripheral effects in mice…

We suggest that (+)-CBD analogues have mixed agonist/antagonist activity in the brain.

Second, (-)-CBD analogues which are devoid of cannabinoid receptor affinity but which inhibit intestinal motility, suggest the existence of a non-CB(1), non-CB(2) receptor.

Therefore, such analogues should be further developed as antidiarrheal and/or antiinflammatory drugs.

We propose to study the therapeutic potential of (-)- and (+)-CBD derivatives for complex conditions such as inflammatory bowel disease and cystic fibrosis.”

http://www.ncbi.nlm.nih.gov/pubmed/15910887

The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain.

“The therapeutic effects of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide were tested in a model of persistent visceral pain (turpentine inflammation of the urinary bladder)…

The results confirm the analgesic potential of endogenous ligands at cannabinoid receptor sites.

The anti-nociceptive effect of the putative CB2 receptor agonist, palmitoylethanolamide, is particularly interesting since it is believed to be a peripherally mediated effect.

This observation might be exploited to separate central psychotropic effects from peripheral analgesic actions of the cannabinoids, under inflammatory conditions.”

http://www.ncbi.nlm.nih.gov/pubmed/9696473

Treatment with a Cannabinoid Receptor 2 Agonist Decreases Severity of Established Cystitis.

“We investigated whether treatment with the selective cannabinoid receptor 2 agonist… would ameliorate the severity of experimental cystitis…

Treatment with a selective cannabinoid receptor 2 agonist decreased severity of established acrolein induced cystitis and inhibited bladder inflammation associated increased referred mechanical sensitivity and increased bladder urinary frequency.

Our data indicate that cannabinoid receptor 2 is a potential therapeutic target for treatment of painful inflammatory bladder diseases.”

http://www.ncbi.nlm.nih.gov/pubmed/24184363

Activation of cannabinoid receptor 2 inhibits experimental cystitis.

“Cannabinoids have been shown to exert analgesic and anti-inflammatory effects, and the effects of cannabinoids are mediated primarily by cannabinoid receptors 1 and 2 (CB1and CB2). Both CB1 and CB2 are present in bladders of various species, including human, monkey, and rodents, and it appears that CB2 is highly expressed in urothelial cells…

The results of the current study indicate that CB2 is a potential therapeutic target for treatment of bladder inflammation and pain in patients.”

http://www.ncbi.nlm.nih.gov/pubmed/23515618

Evaluation of selective cannabinoid CB1 and CB2 receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis.

“Recent experimental results have shown a functional role of the endocannabinoid system in urinary bladder. In this study, we evaluated the anti-inflammatory effect of selective cannabinoid CB1 and CB2 receptor agonists in a mouse model of interstitial cystitis…

Taken together, these findings strongly suggest that modulation of the cannabinoid CB2 receptors might be a promising therapeutic strategy for the treatment of bladder diseases and conditions characterized by inflammation, such as interstitial cystitis.”

http://www.ncbi.nlm.nih.gov/pubmed/24561047

IBD: Patients with IBD find symptom relief in the Cannabis field

“Cannabis (or marijuana) has been used in traditional medicine to treat intestinal inflammation. A survey by Ravikoff Allegretti et al. at a specialized IBD clinic shows that, in the USA, marijuana is used by a substantial number of patients with IBD to alleviate their symptoms.”

http://www.nature.com/nrgastro/journal/vaop/ncurrent/full/nrgastro.2013.245.html